Establishment of a Tissue Registry for Hepatocellular Carcinoma Specimens
TIR-HCC
1 other identifier
observational
500
1 country
1
Brief Summary
The goal of the study is to establish a cancer registry to facilitate research and assist in the identification of additional risk factors for hepatocellular carcinoma. The main objectives are:
- 1.provide a mechanism to store the information about subjects with hepatocellular carcinoma
- 2.use of tissue samples for translational/further research purposes
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2023
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 20, 2023
CompletedStudy Start
First participant enrolled
July 1, 2023
CompletedFirst Posted
Study publicly available on registry
July 7, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2028
July 7, 2023
June 1, 2023
5 years
June 20, 2023
June 28, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Creation of a registry
The primary outcome of this study is to provide a mechanism to store the information about subjects with hepatocellular carcinoma. The outcome will be measured by the number of patients involved in the registry, measured by absolute numbers. The target number is 500 patients.
5 year
Eligibility Criteria
The study population is composed of individuals from Armenian descent who have a biopsy-confirmed diagnosis of hepatocellular carcinoma.
You may qualify if:
- Patients with biopsy-confirmed diagnosis of HCC
- Armenian descent
- Having given their signed Informed consent
You may not qualify if:
- Failure to obtain informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Nikomed Medical Center
Yerevan, Armenia
Related Publications (1)
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
PMID: 33538338BACKGROUND
Related Links
Biospecimen
i. Tumor and liver tissue samples resulting from surgical/biopsy resection ii. 10 mL of whole blood collected on EDTA iii. Stool samples for further gut microbiota profiling
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Hasmik Ghazinian, MD
Nikomed Medical Center
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 5 Years
- Sponsor Type
- NETWORK
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 20, 2023
First Posted
July 7, 2023
Study Start
July 1, 2023
Primary Completion (Estimated)
July 1, 2028
Study Completion (Estimated)
July 1, 2028
Last Updated
July 7, 2023
Record last verified: 2023-06